245 related articles for article (PubMed ID: 22192540)
21. Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trial.
Keitel W; Groth N; Lattanzi M; Praus M; Hilbert AK; Borkowski A; Tsai TF
Vaccine; 2010 Jan; 28(3):840-8. PubMed ID: 19835829
[TBL] [Abstract][Full Text] [Related]
22. A new intranasal influenza vaccine based on a novel polycationic lipid--ceramide carbamoyl-spermine (CCS) I. Immunogenicity and efficacy studies in mice.
Joseph A; Itskovitz-Cooper N; Samira S; Flasterstein O; Eliyahu H; Simberg D; Goldwaser I; Barenholz Y; Kedar E
Vaccine; 2006 May; 24(18):3990-4006. PubMed ID: 16516356
[TBL] [Abstract][Full Text] [Related]
23. Type I IFN is a powerful mucosal adjuvant for a selective intranasal vaccination against influenza virus in mice and affects antigen capture at mucosal level.
Bracci L; Canini I; Puzelli S; Sestili P; Venditti M; Spada M; Donatelli I; Belardelli F; Proietti E
Vaccine; 2005 Apr; 23(23):2994-3004. PubMed ID: 15811645
[TBL] [Abstract][Full Text] [Related]
24. Intranasal administration of a proteosome-influenza vaccine is well-tolerated and induces serum and nasal secretion influenza antibodies in healthy human subjects.
Treanor J; Nolan C; O'Brien D; Burt D; Lowell G; Linden J; Fries L
Vaccine; 2006 Jan; 24(3):254-62. PubMed ID: 16129526
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of the cellular immune responses induced by a non-adjuvanted inactivated whole virus A/H5N1/VN/1203 pandemic influenza vaccine in humans.
Crowe BA; Brühl P; Gerencer M; Schwendinger MG; Pilz A; Kistner O; Koelling-Schlebusch K; Aichinger G; Singer J; Zeitlinger M; Müller M; Ehrlich H; Barrett PN
Vaccine; 2010 Dec; 29(2):166-73. PubMed ID: 21055500
[TBL] [Abstract][Full Text] [Related]
26. Incorporation of LpxL1, a detoxified lipopolysaccharide adjuvant, in influenza H5N1 virosomes increases vaccine immunogenicity.
de Vries JJ; Bungener L; Ter Veer W; van Alphen L; van der Ley P; Wilschut J; Huckriede A
Vaccine; 2009 Feb; 27(6):947-55. PubMed ID: 19059296
[TBL] [Abstract][Full Text] [Related]
27. An α-GalCer analogue with branched acyl chain enhances protective immune responses in a nasal influenza vaccine.
Lee YS; Lee KA; Lee JY; Kang MH; Song YC; Baek DJ; Kim S; Kang CY
Vaccine; 2011 Jan; 29(3):417-25. PubMed ID: 21087689
[TBL] [Abstract][Full Text] [Related]
28. Cross-clade protection against HPAI H5N1 influenza virus challenge in BALB/c mice intranasally administered adjuvant-combined influenza vaccine.
Yang P; Tang C; Luo D; Zhan Z; Xing L; Duan Y; Jia W; Peng D; Liu X; Wang X
Vet Microbiol; 2010 Nov; 146(1-2):17-23. PubMed ID: 20888151
[TBL] [Abstract][Full Text] [Related]
29. Cross-protection against influenza virus infection by intranasal administration of M2-based vaccine with chitosan as an adjuvant.
Sui Z; Chen Q; Wu R; Zhang H; Zheng M; Wang H; Chen Z
Arch Virol; 2010 Apr; 155(4):535-44. PubMed ID: 20195654
[TBL] [Abstract][Full Text] [Related]
30. CAF01 liposomes as a mucosal vaccine adjuvant: In vitro and in vivo investigations.
Christensen D; Foged C; Rosenkrands I; Lundberg CV; Andersen P; Agger EM; Nielsen HM
Int J Pharm; 2010 May; 390(1):19-24. PubMed ID: 19879346
[TBL] [Abstract][Full Text] [Related]
31. A thermosensitive hydrogel based on quaternized chitosan and poly(ethylene glycol) for nasal drug delivery system.
Wu J; Wei W; Wang LY; Su ZG; Ma GH
Biomaterials; 2007 Apr; 28(13):2220-32. PubMed ID: 17291582
[TBL] [Abstract][Full Text] [Related]
32. The novel adjuvant CoVaccineHT increases the immunogenicity of cell-culture derived influenza A/H5N1 vaccine and induces the maturation of murine and human dendritic cells in vitro.
Bodewes R; Geelhoed-Mieras MM; Heldens JG; Glover J; Lambrecht BN; Fouchier RA; Osterhaus AD; Rimmelzwaan GF
Vaccine; 2009 Nov; 27(49):6833-9. PubMed ID: 19772942
[TBL] [Abstract][Full Text] [Related]
33. Safety and immunogenicity of an influenza vaccine A/H5N1 (A/Vietnam/1194/2004) when coadministered with a heat-labile enterotoxin (LT) adjuvant patch.
Glenn GM; Thomas DN; Poffenberger KL; Flyer DC; Ellingsworth LR; Andersen BH; Frech SA
Vaccine; 2009 Dec; 27 Suppl 6():G60-6. PubMed ID: 20006142
[TBL] [Abstract][Full Text] [Related]
34. Humoral and cellular immune responses to split-virion H5N1 influenza vaccine in young and elderly adults.
Leroux-Roels I; Van der Wielen M; Kafeja F; Vandermeulen C; Lazarus R; Snape MD; John T; Carre C; Nougarede N; Pepin S; Leroux-Roels G; Hoppenbrouwers K; Pollard AJ; Van Damme P
Vaccine; 2009 Nov; 27(49):6918-25. PubMed ID: 19761837
[TBL] [Abstract][Full Text] [Related]
35. Identification of HLA class II H5N1 hemagglutinin epitopes following subvirion influenza A (H5N1) vaccination.
Zinckgraf JW; Sposato M; Zielinski V; Powell D; Treanor JJ; von Hofe E
Vaccine; 2009 Aug; 27(39):5393-401. PubMed ID: 19596415
[TBL] [Abstract][Full Text] [Related]
36. Vaccination with whole inactivated virus vaccine affects the induction of heterosubtypic immunity against influenza virus A/H5N1 and immunodominance of virus-specific CD8+ T-cell responses in mice.
Bodewes R; Kreijtz JH; Hillaire ML; Geelhoed-Mieras MM; Fouchier RA; Osterhaus AD; Rimmelzwaan GF
J Gen Virol; 2010 Jul; 91(Pt 7):1743-53. PubMed ID: 20335492
[TBL] [Abstract][Full Text] [Related]
37. Intranasal Immunization Using Mannatide as a Novel Adjuvant for an Inactivated Influenza Vaccine and Its Adjuvant Effect Compared with MF59.
Ren ST; Zhang XM; Sun PF; Sun LJ; Guo X; Tian T; Zhang J; Guo QY; Li X; Guo LJ; Che J; Wang B; Zhang H
PLoS One; 2017; 12(1):e0169501. PubMed ID: 28052136
[TBL] [Abstract][Full Text] [Related]
38. Protection against influenza virus infection by intranasal vaccine with surf clam microparticles (SMP) as an adjuvant.
Ichinohe T; Watanabe I; Tao E; Ito S; Kawaguchi A; Tamura S; Takahashi H; Sawa H; Moriyama M; Chiba J; Komase K; Suzuki Y; Kurata T; Sata T; Hasegawa H
J Med Virol; 2006 Jul; 78(7):954-63. PubMed ID: 16721854
[TBL] [Abstract][Full Text] [Related]
39. Novel vaccine delivery system induces robust humoral and cellular immune responses based on multiple mechanisms.
Wang YQ; Wu J; Fan QZ; Zhou M; Yue ZG; Ma GH; Su ZG
Adv Healthc Mater; 2014 May; 3(5):670-81. PubMed ID: 24574270
[TBL] [Abstract][Full Text] [Related]
40. Oral spray immunization may be an alternative to intranasal vaccine delivery to induce systemic antibodies but not nasal mucosal or cellular immunity.
Bakke H; Samdal HH; Holst J; Oftung F; Haugen IL; Kristoffersen AC; Haugan A; Janakova L; Korsvold GE; Krogh G; Andersen EA; Djupesland P; Holand T; Rappuoli R; Haneberg B
Scand J Immunol; 2006 Mar; 63(3):223-31. PubMed ID: 16499576
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]